FORTUNE -- Private equity firm Clayton Dubilier & Rice today said that it has completed its previously-announced acquisition of a majority stake in PharMEDium from Oak Investment Partners and Baird Capital.
No financial terms were disclosed, but Fortune has learned that the deal was done at around a $900 million enterprise valuation.
For Oak this represents around a 6x return on its 2007 investment, when it paid around $67 million to acquire an equity stake from Baird (which retained part of its position).
PharMEDium is a Lake Forrest, Ill.–based provider of hospital pharmacy sterile compounding services.
Sign up for Dan Primack's daily email newsletter on deals and deal-makers: GetTermSheet.com
|The Deep Web you don't know about|
|Premarkets: Is the market calm here to stay?|
|House panel to investigate GM response to problem linked to 13 deaths|
|Pizza chain Sbarro files for bankruptcy|
|More trouble for Boeing's Dreamliner|